The Cancer Center requests $461,731 in annual Developmental Funds to allow the following: 1) Recruitment of new clinical oncologists especially related to Surgical Oncology and Medical Oncology, and basic and translation scientists for our three scientific programs. 2) Support for our pilot project program that is vital to our ability to grow the programs as needed. 3) Support for Shared Resources in Development that are crucial to our ability to provide Cancer Center investigators with the research infrastructure required to meet future programmatic goals. 4) Retention of critical members of the Cancer Center. 5) Bridging of funding for Cancer Center members to redirect their laboratories to a high priority cancer research area to increase their funding potential. The past developmental funds were used in response to the advice of our External Advisory Board (EAB) and our internal advisory committees. To continue to respond to the strategic planning process identified by both our EAB and internal advisory committees, the Cancer Center must invest in further recruitment of high priority senior basic scientists and physician-scientists with a strong cancer focus in organ-specific cancers. The Cancer Center considers continued support for the pilot project program, which was very successful during the past grant period, as key to programmatic growth and innovation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-17
Application #
7944707
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-08-03
Project End
2012-07-31
Budget Start
2009-08-03
Budget End
2010-07-31
Support Year
17
Fiscal Year
2009
Total Cost
$267,688
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:

Showing the most recent 10 out of 989 publications